A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

@article{Nabors2012ASR,
  title={A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).},
  author={Louis Burt Nabors and Thomas R. Mikkelsen and Monika E Hegi and Xiaubu Ye and Tracy Batchelor and Glenn Jay Lesser and David M. Peereboom and Myrna R Rosenfeld and Jeff Olsen and Steve Brem and Joy D. Fisher and Stuart Grossman},
  journal={Cancer},
  year={2012},
  volume={118 22},
  pages={5601-7}
}
BACKGROUND Cilengitide is a selective integrin inhibitor that is well tolerated and has demonstrated biologic activity in patients with recurrent malignant glioma. The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing. METHODS In total, 112 patients were accrued. Eighteen… CONTINUE READING